SGTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Notice: This stock is marked as potentially delisted. It may not be actively trading.

Insider Ownership Percentage: 6.50%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $0.00

Sigilon Therapeutics Insider Trading History Chart

Sigilon Therapeutics Share Price & Price History

^$22.47

+0.30 (1.20%)

As of 08/11/2023 01:00 AM ET

Sigilon Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/11/2023	Lilly & Co Eli	Major Shareholder	Buy	1,718,493	$14.92	$25,639,915.56	100

SEC Filings (Institutional Ownership Changes) for Sigilon Therapeutics (NASDAQ:SGTX)

Institutional Buying and Selling by Quarter

Sigilon Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
8/9/2023	Canada Pension Plan Investment Board	114,244	$2.57M	0.0%	-92.3%	4.566%
5/1/2023	Virtu Financial LLC	27,596	$26K	0.0%	+148.2%	0.085%
2/10/2022	Acadian Asset Management LLC	11,100	$30K	0.0%	N/A	0.034%
1/18/2022	Soundmark Wealth Management LLC	25,555	$71K	0.0%	-49.5%	0.079%
11/12/2021	Geode Capital Management LLC	231,662	$1.31M	0.0%	+73.2%	0.723%
11/10/2021	American Century Companies Inc.	359,688	$2.03M	0.0%	+10.7%	1.122%
11/10/2021	Goldman Sachs Group Inc.	47,860	$0.27M	0.0%	+42.6%	0.149%
11/10/2021	Healthcare of Ontario Pension Plan Trust Fund	229,500	$1.30M	0.0%	N/A	0.716%
11/9/2021	BlackRock Inc.	1,740,942	$9.84M	0.0%	+24.0%	5.430%
11/4/2021	Choate Investment Advisors	66,666	$0.38M	0.0%	N/A	0.208%
11/4/2021	Deutsche Bank AG	19,008	$0.11M	0.0%	+303.5%	0.059%
8/16/2021	Morgan Stanley	546,942	$5.87M	0.0%	+26,803.2%	1.706%
8/16/2021	Goldman Sachs Group Inc.	33,552	$0.36M	0.0%	+70.8%	0.105%

Data available starting January 2016

Sigilon Therapeutics, Inc., a preclinical stage biotechnology company, develops functional cures for patients with acute and chronic diseases. Its lead product candidate is SIG-002 to replace islet cells for the treatment of type 1 diabetes; and SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-205, SIG-218, SIG-220, and SIG-005, which are to treat the non-neurological manifestations of mucopolysaccharidosis type 1; and SIG-207 is to treat of Fabry disease. Sigilon Therapeutics, Inc. has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for the treatment of Type 1 Diabetes. The company was formerly known as Sigilon, Inc. and changed its name to Sigilon Therapeutics, Inc. in June 2017. Sigilon Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $22.47

$22.47

50 Day Range

MA: $22.02

$20.92

$23.06

52 Week Range

Now: $22.47

$3.77

$28.00

Volume

N/A

Average Volume

62,902 shs

Market Capitalization

$56.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

4.12